




Instance: composition-en-bbb651a1913e568b3035dea752ef36ea
InstanceOf: CompositionUvEpi
Title: "Composition for ivabradine Package Leaflet"
Description:  "Composition for ivabradine Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp9f905123b19c0e055435474ad8fd13e5)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - ivabradine"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Ivabradine Zentiva is and what it is used for </li>
<li>What you need to know before you take Ivabradine Zentiva </li>
<li>How to take Ivabradine Zentiva </li>
<li>Possible side effects </li>
<li>How to store Ivabradine Zentiva </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What ivabradine is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What ivabradine is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Ivabradine Zentiva (ivabradine) is a heart medicine used to treat: </p>
<p>Symptomatic stable angina pectoris (which causes chest pain) in adult patients whose heart rate 
is over or equal to 70 beats per minute. It is used in adult patients who do not tolerate or cannot take 
heart medicines called beta-blockers. It is also used in combination with beta-blockers in adult 
patients whose condition is not fully controlled with a beta-blocker. </p>
<p>Chronic heart failure in adult patients whose heart rate is over or equal to 75 beats per minute. 
It is used in combination with standard therapy, including beta-blocker therapy or when beta-
blockers are contraindicated or not tolerated. </p>
<p>About stable angina pectoris (usually referred to as  angina ) </p>
<p>Stable angina is a heart disease which happens when the heart does not receive enough oxygen. The most 
common symptom of angina is chest pain or discomfort.  </p>
<p>About chronic heart failure </p>
<p>Chronic heart failure is a heart disease which happens when your heart cannot pump enough blood 
to the rest of your body. The most common symptoms of heart failure are breathlessness, fatigue, tiredness 
and ankle swelling. </p>
<p>How does Ivabradine Zentiva work? </p>
<p>The specific heart rate lowering action of ivabradine helps: 
  to control and reduce the number of angina attacks by lowering heart s need for oxygen, 
  to improve the heart functioning and vital prognosis in  patients with chronic heart failure. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take ivabradine"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take ivabradine"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Ivabradine Zentiva </p>
<p>if you are allergic to ivabradine or any of the other ingredients of this medicine (listed in section 6). </p>
<p>if your resting heart rate before treatment is too slow (below 70 beats per minute). </p>
<p>if you are suffering from cardiogenic shock (a heart condition treated in hospital). </p>
<p>if you suffer from a heart rhythm disorder (sick sinus syndrome, sino-atrial block, AV-block of 3rd 
degree). </p>
<p>if you are having a heart attack. </p>
<p>if you suffer from very low blood pressure. </p>
<p>if you suffer from unstable angina (a severe form in which chest pain occurs very frequently and 
with or without exertion). </p>
<p>if you have heart failure which has recently become worse. </p>
<p>if your heartbeat is exclusively imposed by your pacemaker. </p>
<p>if you suffer from severe liver problems. </p>
<p>if you are already taking medicines for the treatment of fungal infections (such as ketoconazole, 
itraconazole), macrolide antibiotics (such as josamycin, clarithromycin, telithromycin 
or erythromycin given orally), medicines to treat HIV infections (such as nelfinavir, ritonavir) 
or nefazodone (medicine to treat depression) or diltiazem, verapamil (used for high blood pressure 
or angina pectoris). </p>
<p>if you are a woman able to have children and not using reliable contraception. </p>
<p>if you are pregnant or trying to become pregnant. </p>
<p>if you are breast-feeding. </p>
<p>Warnings and precautions 
Talk to your doctor or pharmacist before taking Ivabradine Zentiva </p>
<p>if you suffer from heart rhythm disorders (such as irregular heartbeat, palpitation, increase in chest 
pain) or sustained atrial fibrillation (a type of irregular heartbeat), or an abnormality 
of electrocardiogram (ECG) called  long QT syndrome . </p>
<p>if you have symptoms such as tiredness, dizziness or shortness of breath (this could mean that your 
heart is slowing down too much). </p>
<p>if you suffer from symptoms of atrial fibrillation (pulse rate at rest unusually high (over 110 beats 
per minute) or irregular, without any apparent reason, making it difficult to measure). </p>
<p>if you have had a recent stroke (cerebral attack). </p>
<p>if you suffer from mild to moderate low blood pressure. </p>
<p>if you suffer from uncontrolled blood pressure, especially after a change in your antihypertensive 
treatment. </p>
<p>if you suffer from severe heart failure or heart failure with abnormality of ECG called  bundle 
branch block . </p>
<p>if you suffer from chronic eye retinal disease. </p>
<p>if you suffer from moderate liver problems. </p>
<p>if you suffer from severe renal problems. </p>
<p>If any of the above applies to you, talk straight away to your doctor before or while taking Ivabradine 
Zentiva. </p>
<p>Children and adolescents 
Do not give this medicine to children and adolescents younger than 18 years. Available data are 
insufficient in this age group. </p>
<p>Other medicines and Ivabradine Zentiva 
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. </p>
<p>Make sure to tell your doctor if you are taking any of the following medicines, as a dose adjustment 
of Ivabradine Zentiva or monitoring should be required: </p>
<p>fluconazole (an antifungal medicine). </p>
<p>rifampicin (an antibiotic). </p>
<p>barbiturates (for difficult sleeping or epilepsy). </p>
<p>phenytoin (for epilepsy). </p>
<p>Hypericum perforatum or St. John s Wort (herbal treatment for depression). </p>
<p>QT prolonging medicines to treat either heart rhythm disorders or other conditions: 
* quinidine, disopyramide, ibutilide, sotalol, amiodarone (to treat heart rhythm disorders). 
* bepridil (to treat angina pectoris). 
* certain types of medicines to treat anxiety, schizophrenia or other psychoses 
(such as pimozide, ziprasidone, sertindole). 
* anti-malarial medicines (such as mefloquine or halofantrine). 
* intravenous erythromycin (an antibiotic). 
* pentamidine (an antiparasitic medicine). 
* cisapride (against the gastro-oesophageal reflux). </p>
<p>Some types of diuretics which may cause decrease in blood potassium level, such as furosemide, 
hydrochlorothiazide, indapamide (used to treat oedema, high blood pressure). </p>
<p>Ivabradine Zentiva with food and drink 
Avoid grapefruit juice during treatment with Ivabradine Zentiva. </p>
<p>Pregnancy and breast-feeding 
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your 
doctor or pharmacist for advice before taking this medicine. 
Do not take Ivabradine Zentiva if you are pregnant or are planning to have a baby (see  Do not take 
Ivabradine Zentiva ). 
If you are pregnant and have taken Ivabradine Zentiva, talk to your doctor. 
Do not take Ivabradine Zentiva if you are able to become pregnant unless you use reliable contraceptive 
measures (see  Do not take Ivabradine Zentiva ). 
Do not take Ivabradine Zentiva if you are breast-feeding (see  Do not take Ivabradine Zentiva ). Talk 
to your doctor if you are breast-feeding or intending to breast-feed as breast-feeding should 
be discontinued if you take Ivabradine Zentiva. </p>
<p>Driving and using machines 
Ivabradine Zentiva may cause temporary luminous visual phenomena (a temporary brightness in the field 
of vision, see  Possible side effects ). If this happens to you, be careful when driving or using machines 
at times when there could be sudden changes in light intensity, especially when driving at night. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take ivabradine"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take ivabradine"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor 
or pharmacist if you are not sure. </p>
<p>If you are being treated for stable angina pectoris </p>
<p>The starting dose should not exceed one tablet of Ivabradine Zentiva 5 mg twice daily. If you still have 
angina symptoms and if you have tolerated the 5 mg twice daily dose well, the dose may be increased. 
The maintenance dose should not exceed 7.5 mg twice daily. Your doctor will prescribe the right dose 
for you. The usual dose is one tablet in the morning and one tablet in the evening. In some cases 
(e.g. if you are aged 75 years or more), your doctor may prescribe half the dose i.e., one half 5 mg tablet 
of Ivabradine Zentiva 5 mg (corresponding to 2.5 mg ivabradine) in the morning and one half 5 mg tablet 
in the evening. </p>
<p>If you are being treated for chronic heart failure </p>
<p>The usual recommended starting dose is one tablet of Ivabradine Zentiva 5 mg twice daily increasing 
if necessary to one tablet of Ivabradine Zentiva 7.5 mg twice daily. Your doctor will decide the right dose 
for you. The usual dose is one tablet in the morning and one tablet in the evening. In some cases 
(e.g. if you are aged 75 years or more), your doctor may prescribe half the dose i.e., one half 5 mg tablet 
of Ivabradine Zentiva 5 mg (corresponding to 2.5 mg ivabradine) in the morning and one half 5 mg tablet 
in the evening. </p>
<p>Method of administration 
Tablets must be taken orally twice daily, i.e. once in the morning and once in the evening during meals. 
Ivabradine Zentiva 5 mg film-coated tablet can be divided into equal doses. Use a tablet cutter to divide 
the tablet. </p>
<p>If you take more Ivabradine Zentiva than you should 
A large dose of Ivabradine Zentiva could make you feel breathless or tired because your heart slows down 
too much. If this happens, contact your doctor immediately. </p>
<p>If you forget to take Ivabradine Zentiva 
If you forget to take a dose of Ivabradine Zentiva, take the next dose at the usual time. Do not take 
a double dose to make up for a forgotten dose. </p>
<p>If you stop taking Ivabradine Zentiva 
As the treatment for angina or chronic heart failure is usually life-long, you should discuss with your 
doctor before stopping this medicinal product. 
If you think that the effect of Ivabradine Zentiva is too strong or too weak, talk to your doctor 
or pharmacist. 
If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>The most common adverse reactions with this medicine are dose dependent and related to its mode 
of action: </p>
<p>Very common (may affect more than 1 in 10 people) </p>
<p>Luminous visual phenomena (brief moments of increased brightness, most often caused by sudden 
changes in light intensity). They can also be described as a halo, coloured flashes, image 
decomposition or multiple images. They generally occur within the first two months of treatment 
after which they may occur repeatedly and resolve during or after treatment. </p>
<p>Common (may affect up to 1 in 10 people) </p>
<p>Modification in the heart functioning (the symptoms are a slowing down of the heart rate). They 
particularly occur within the first 2 to 3 months of treatment initiation. </p>
<p>Other side effects have also been reported: </p>
<p>Common (may affect up to 1 in 10 people) </p>
<p>Irregular rapid contraction of the heart (atrial fibrillation), abnormal perception of heartbeat 
(bradycardia, ventricular extrasystoles, AV 1st degree block (ECG prolonged PQ interval)), 
uncontrolled blood pressure, headache, dizziness and blurred vision (cloudy vision). </p>
<p>Uncommon (may affect up to 1 in 100 people) </p>
<p>Palpitations and cardiac extra beats, feeling sick (nausea), constipation, diarrhoea, abdominal pain, 
spinning sensation (vertigo), difficulty breathing (dyspnoea), muscle spasms, high blood levels of 
uric acid, an excess of eosinophils (a type of white blood cell) and elevated creatinine in blood (a 
breakdown product of muscle), skin rash, angioedema (such as swollen face, tongue or throat, 
difficulty in breathing or swallowing), low blood pressure, fainting, feeling of tiredness, feeling of 
weakness, abnormal ECG heart tracing, double vision, impaired vision. </p>
<p>Rare (may affect up to 1 in 1 000 people) </p>
<p>Urticaria, itching, skin reddening, feeling unwell. </p>
<p>Very rare (may affect up to 1 in 10 000 people) </p>
<p>Irregular heartbeats (AV 2nd and 3rd degree block, sick sinus syndrome). </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not 
listed in this leaflet. You can also report side effects directly via the national reporting system listed 
in Appendix V.  By reporting side effects you can help provide more information on the safety of this 
medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store ivabradine"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store ivabradine"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the carton and blister after  EXP . 
The expiry date refers to the last day of that month. </p>
<p>Store below 25  C. Store in the original package in order to protect from moisture. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw 
away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Ivabradine Zentiva contains </p>
<p>The active substance is ivabradine (as hydrochloride). Each film-coated tablet contains 5 mg 
ivabradine (as hydrochloride) or 7.5 mg ivabradine (as hydrochloride). </p>
<p>The other ingredients are: 
tablet core: mannitol, crospovidone (type A), magnesium stearate,<br />
film-coating: hypromellose (6 mPa s, type 2910), titanium dioxide (E172), macrogol 400, glycerol 
(E422). </p>
<p>What Ivabradine Zentiva looks like and contents of the pack 
Ivabradine Zentiva 5 mg film-coated tablets are round, biconvex white tablets with deep breakline on one 
side and  5  debossing on other side with diameter 6.5 mm. The tablet can be divided into equal doses. 
Ivabradine Zentiva 7.5 mg film-coated tablets are white to off white, round tablets with diameter 7.1 mm. 
Ivabradine Zentiva is packed in OPA/Alu/PVC-Alu blisters and in paper carton. </p>
<p>Tablets are available in packs of 14, 28, 56, 84, 98, 100, 112 film-coated tablets. </p>
<p>Not all pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder 
Zentiva, k.s. 
U Kabelovny 102 37 Prague Czech Republic </p>
<p>Manufacturer(s) 
Zentiva, k.s. 
U Kabelovny 102 37 Prague Czech Republic </p>
<p>or </p>
<p>S.C. Zentiva S.A 
50 Theodor Pallady Blvd, 
District 3, 
032266 Bucharest 
Romania </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: </p>
<p>Belgi /Belgique/Belgien 
Zentiva, k.s. 
T l/Tel: +32 280 86 PV-Belgium@zentiva.com </p>
<p>Lietuva 
Zentiva, k.s. 
Tel: +370 52152PV-Lithuania@zentiva.com </p>
<p>Zentiva, k.s. 
 : + 35924417PV-Bulgaria@zentiva.com </p>
<p>Luxembourg/Luxemburg 
Zentiva, k.s. 
T l/Tel: +352 208 82PV-Luxembourg@zentiva.com 
 esk  republika 
Zentiva, k.s. 
Tel: +420 267 241 PV-Czech-Republic@zentiva.com 
Magyarorsz g 
Zentiva Pharma Kft. 
Tel.: +36 1 299 1PV-Hungary@zentiva.com 
Danmark 
Zentiva Denmark ApS 
Tlf: +45 787 68 PV-Denmark@zentiva.com </p>
<p>Malta 
Zentiva, k.s. 
Tel: +356 2778 0PV-Malta@zentiva.com 
Deutschland 
Zentiva Pharma GmbH<br />
Tel: +49 (0) 800 53 53 PV-Germany@zentiva.com </p>
<p>Nederland 
Zentiva, k.s. 
Tel: +31 202 253 PV-Netherlands@zentiva.com 
Eesti 
Zentiva, k.s. 
Tel: +372 52 70PV-Estonia@zentiva.com </p>
<p>Norge 
Zentiva Denmark ApS 
Tlf: +47 219 66 PV-Norway@zentiva.com </p>
<p>Zentiva, k.s. 
 : +30 211 198 7PV-Greece@zentiva.com </p>
<p>sterreich 
Zentiva, k.s. 
Tel: +43 720 778 PV-Austria@zentiva.com 
Espa a 
Zentiva, k.s. 
Tel: +34 931 815 PV-Spain@zentiva.com </p>
<p>Polska 
Zentiva Polska Sp. z o.o. 
Tel: + 48 22 375 92 PV-Poland@zentiva.com 
France 
Zentiva France 
T l: +33 (0) 800 089 PV-France@zentiva.com </p>
<p>Portugal 
Zentiva Portugal, Lda 
Tel: +351210601PV-Portugal@zentiva.com 
Hrvatska 
Zentiva d.o.o. 
Tel: +385 1 6641 PV-Croatia@zentiva.com </p>
<p>Rom nia 
ZENTIVA S.A. 
Tel: +4 021.304.7PV-Romania@zentiva.com </p>
<p>Ireland 
Zentiva, k.s. 
Tel: +353 818 882 PV-Ireland@zentiva.com </p>
<p>Slovenija 
Zentiva, k.s. 
Tel: +386 360 00 PV-Slovenia@zentiva.com 
 sland 
Zentiva Denmark ApS 
S mi: +354 539 0PV-Iceland@zentiva.com </p>
<p>Slovensk  republika 
Zentiva, a.s. 
Tel: +421 2 3918 3PV-Slovakia@zentiva.com 
Italia 
Zentiva Italia S.r.l. 
Tel: +39-02-38598PV-Italy@zentiva.com 
Suomi/Finland 
Zentiva Denmark ApS 
Puh/Tel: +358 942 598 PV-Finland@zentiva.com </p>
<p>Zentiva, k.s. 
 : +357 240 30 PV-Cyprus@zentiva.com </p>
<p>Sverige 
Zentiva Denmark ApS 
Tel: +46 840 838 PV-Sweden@zentiva.com 
Latvija 
Zentiva, k.s. 
Tel: +371 67893PV-Latvia@zentiva.com 
United Kingdom (Northern Ireland) 
Zentiva, k.s. 
Tel: +44 (0) 800 090 2PV-United-Kingdom@zentiva.com </p>
<p>This leaflet was last revised in  </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-bbb651a1913e568b3035dea752ef36ea
InstanceOf: CompositionUvEpi
Title: "Composition for ivabradine Package Leaflet"
Description:  "Composition for ivabradine Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp9f905123b19c0e055435474ad8fd13e5)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - ivabradine"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen 
1. Virkning og anvendelse<br />
2. Det skal du vide, før du begynder at tage Ivabradine Zentiva 
3. Sådan skal du tage Ivabradine Zentiva 
4. Bivirkninger 
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What ivabradine is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What ivabradine is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Ivabradine Zentiva (ivabradin) er hjertemedicin, som anvendes til behandling af:</p>
<ul>
<li>Symptomerne ved stabil angina pectoris (en lidelse, som forårsager smerter i brystet) hos voksne 
patienter med en puls på mindst 70 slag i minuttet. Det anvendes til voksne patienter, som ikke 
kan tåle eller ikke kan anvende hjertemedicin af typen betablokkere. Det anvendes også i 
kombination med betablokkere til voksne patienter, hvis sygdom ikke er fuldstændigt kontrolleret 
med en betablokker.  </li>
<li>Kronisk hjertesvigt hos voksne patienter med en puls på mindst 75 slag i minuttet. Ivabradine 
Zentiva bruges sammen med standardbehandling med betablokker, eller når patienten ikke må få 
eller ikke kan tåle betablokker. </li>
</ul>
<p>Stabil angina pectoris (også kaldet "hjertekrampe") </p>
<p>Stabil hjertekrampe er en hjertesygdom, som opstår, når hjertet ikke får tilstrækkeligt med ilt. De mest 
almindelige symptomer på hjertekrampe er smerter eller ubehag i brystet.  </p>
<p>Kronisk hjertesvigt </p>
<p>Kronisk hjertesvigt er en hjertesygdom, der opstår, når hjertet ikke kan pumpe tilstrækkeligt blod rundt 
til resten af kroppen. De almindeligste symptomer på hjertesvigt er åndenød, træthed, udmattelse og 
hævede ankler.  </p>
<p>Sådan virker Ivabradine Zentiva </p>
<p>Ivabradins specifikke pulsenedsættende virkning hjælper:</p>
<ul>
<li>med at kontrollere og mindske antallet af anfald af hjertekrampe ved at nedsætte hjertets behov for 
ilt,  </li>
<li>med at forbedre hjertefunktionen og prognosen hos patienter med kronisk hjertesvigt. </li>
</ul>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take ivabradine"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take ivabradine"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Ivabradine Zentiva 
- hvis du er allergisk over for ivabradin eller et af de øvrige indholdsstoffer i Ivabradine Zentiva 
(angivet i punkt 6). 
- hvis din hjertefrekvens i hvile før behandlingen er for langsom (under 70 slag i minuttet). 
- hvis du lider af kardiogent shock (en hjertesygdom, som skal behandles på hospital).<br />
- hvis du lider af forstyrrelser i hjertets rytme (syg sinus-syndrom, sinuatrialt blok, AV-blok af 3. grad).<br />
- hvis du får et hjerteanfald. 
- hvis du lider af meget lavt blodtryk. 
- hvis du lider af ustabil hjertekrampe (en alvorlig form med hyppige brystsmerter, der opstår 
både under hvile og anstrengelse).<br />
- hvis du lider af hjertesvigt, og din tilstand for nylig er forværret.<br />
- hvis din hjerterytme udelukkende styres af en pacemaker. 
- hvis du lider af svære leverproblemer. 
- hvis du allerede tager medicin til behandling af svampeinfektioner (f.eks. ketoconazol, 
itraconazol), makrolidantibiotika (f.eks. josamycin, clarithromycin, telithromycin eller 
erythromycin givet oralt) eller medicin til behandling af hiv-infektioner (som f.eks. nelfinavir 
ritonavir) eller nefazodon (medicin til behandling af depressioner) eller diltiazem, verapamil 
(bruges til for højt blodtryk eller angina pectoris).<br />
- hvis du er en kvinde i den fødedygtige alder og ikke anvender sikker prævention.<br />
- hvis du er gravid eller forsøger at blive gravid. 
- hvis du ammer.  </p>
<p>Advarsler og forsigtighedsregler 
- Kontakt lægen eller apotekspersonalet, før du tager Ivabradine Zentiva 
- hvis du lider af forstyrrelser i hjertets rytme (uregelmæssig puls, hjertebanken, smerter i 
brystkassen) eller vedvarende hjerteflimmer (hurtig, meget uregelmæssig puls) eller en 
abnormitet i elektrokardiogrammet (ekg) kaldet "lang QT-syndrom".<br />
- hvis du har symptomer som træthed, svimmelhed eller kortåndethed (det kan betyde, at dit 
hjerte slår for langsomt).<br />
- hvis du lider af symptomer på atrieflimren (hvilepulsen er usædvanlig høj (over 110 slag i 
minuttet) eller uregelmæssig uden nogen tydelig grund, hvilket gør det vanskeligt at måle 
pulsen).<br />
- hvis du for nylig har haft et slagtilfælde (blodprop i hjernen/hjerneblødning).<br />
- hvis du lider af lavt blodtryk i let til moderat grad. 
- hvis dit blodtryk ikke er under kontrol - især efter en ændring i din blodtryksbehandling.<br />
- hvis du lider af alvorligt hjertesvigt eller hjertesvigt med en abnormitet i ekg kaldet 
"grenblok".<br />
- hvis du lider af en kronisk nethindesygdom i øjet.<br />
- hvis du lider af moderate leverproblemer. 
- hvis du lider af svære problemer med nyrerne.  </p>
<p>Hvis noget af ovenstående gælder for dig, skal du straks tale med din læge om det, før eller mens<br />
du tager Ivabradine Zentiva. </p>
<p>Børn og unge<br />
Dette lægemiddel må ikke gives til børn og unge under 18 år. Der findes ikke tilstrækkelige data hos 
denne aldersgruppe. </p>
<p>Brug af anden medicin sammen med Ivabradine Zentiva 
Fortæl altid lægen eller apotekspersonalet, hvis du tager anden medicin, for nylig har taget andet 
medicin eller planlægger at tage anden medicin. 
Det er vigtigt, at du fortæller det til din læge, hvis du tager nogle af følgende lægemidler, da det kan 
blive nødvendigt at justere dosis af Ivabradine Zentiva eller kontrollere dig nøjere:</p>
<ul>
<li>fluconazol (mod svampeinfektioner).  </li>
<li>rifampicin (et antibiotikum). </li>
<li>barbiturater (mod søvnforstyrrelser eller epilepsi). </li>
<li>phenytoin (mod epilepsi).  </li>
<li>Hypericum perforatum eller perikon (naturmedicin mod depression).  </li>
<li>
<p>medicin, der forlænger QT-intervallet i ekg til behandling af enten hjerterytmeforstyrrelser eller 
andre sygdomme: </p>
</li>
<li>
<p>quinidin, disopyramid, ibutilid, sotalol, amiodaron (til behandling af forstyrrelser af 
hjertets rytme). </p>
</li>
<li>
<p>bepridil (til behandling af angina pectoris).  </p>
</li>
<li>
<p>visse lægemidler til behandling af angst, skizofreni eller andre alvorlige sindslidelser 
(f.eks. pimozid, ziprasidon og sertindol).  </p>
</li>
<li>
<p>malariamidler (f.eks. mefloquin eller halofantrin). </p>
</li>
<li>
<p>intravenøs erythromycin (et antibiotikum).  </p>
</li>
<li>
<p>pentamidin (et lægemiddel mod parasitter). </p>
</li>
<li>
<p>cisaprid (mod tilbageløb af mavesyre fra mavesæk til spiserør). </p>
</li>
<li>nogle typer vanddrivende medicin (diuretika), der kan medføre nedsat kaliumniveau i blodet, 
såsom furosemid, hydrochlorthiazid, indapamid (anvendt til at behandle ødemer og højt blodtryk).  </li>
</ul>
<p>Brug af Ivabradine Zentiva sammen med mad og drikke 
Undgå grapefrugtjuice under behandling med Ivabradine Zentiva. </p>
<p>Graviditet og amning<br />
Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal 
du spørge din læge eller apotekspersonalet til råds, før du tager dette lægemiddel. 
Du må ikke tage Ivabradine Zentiva, hvis du er gravid eller planlægger at blive gravid (se under "Tag 
ikke Ivabradine Zentiva"). 
Tal med din læge, hvis du er gravid og har taget Ivabradine Zentiva.<br />
Tag ikke Ivabradine Zentiva, hvis du kan blive gravid, medmindre du anvender sikker prævention (se 
"Tag ikke Ivabradine Zentiva"). 
Du må ikke tage Ivabradine Zentiva, hvis du ammer (se under "Tag ikke Ivabradine Zentiva"). 
Tal med lægen, hvis du ammer eller ønsker at amme, da amning skal ophøre, hvis du tager Ivabradine 
Zentiva.  </p>
<p>Trafik- og arbejdssikkerhed 
Ivabradine Zentiva kan forårsage forbigående lysfænomener (forbigående lysglimt i synsfeltet, se 
under "Bivirkninger"). Hvis du får det, skal du udvise forsigtighed, når du kører bil eller betjener 
maskiner, specielt på tidspunkter, hvor der kan forekomme pludselige ændringer i lysintensiteten, især 
ved nattekørsel.  </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take ivabradine"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take ivabradine"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens eller apotekspersonalets anvisning. Er du i tvivl, så spørg 
lægen eller apotekspersonalet.  </p>
<p>Hvis du bliver behandlet for stabil angina pectoris  </p>
<p>Startdosis bør ikke være mere end en Ivabradine Zentiva-tablet på 5 mg to gange dagligt. Hvis du 
stadig har symptomer på angina, og hvis du har tålt dosis på 5 mg to gange dagligt godt, kan dosis 
øges. Vedligeholdelsesdosis bør ikke være højere end 7,5 mg to gange dagligt. Din læge vil ordinere 
den rette dosis til dig. Den sædvanlige dosis er en tablet om morgenen og en tablet om aftenen. I nogle 
tilfælde (f.eks. hvis du er 75 år eller ældre) kan din læge halvere dosis, dvs. en halv Ivabradine 
Zentiva-tablet på 5 mg (svarende til 2,5 mg ivabradin) om morgenen og en halv tablet på 5 mg om 
aftenen.  </p>
<p>Hvis du bliver behandlet for kronisk hjertesvigt  </p>
<p>Den sædvanlige startdosis er en Ivabradine Zentiva-tablet på 5 mg to gange dagligt, og den kan om 
nødvendigt øges til en Ivabradine Zentiva-tablet på 7,5 mg to gange dagligt. Din læge fastsætter den 
rette dosis til dig. Den sædvanlige dosis er en tablet om morgenen og en tablet om aftenen. I nogle 
tilfælde (f.eks. hvis du er 75 år eller ældre) kan din læge halvere dosis, dvs. en halv Ivabradine 
Zentiva-tablet på 5 mg (svarende til 2,5 mg ivabradin) om morgenen og en halv tablet på 5 mg om 
aftenen.  </p>
<p>Administration 
Tabletterne skal tages oralt to gange dagligt, dvs. én tablet om morgenen og én om aftenen i 
forbindelse med et måltid. Ivabradine Zentiva 5 mg filmovertrukne tabletter kan deles i to lige store 
doser. Brug en tabletskærer til at dele tabletten. </p>
<p>Hvis du har taget for mange Ivabradine Zentiva 
En stor dosis Ivabradine Zentiva kan få dig til at føle dig kortåndet eller træt, fordi dit hjerte slår for 
langsomt. Hvis det sker, skal du straks kontakte din læge.  </p>
<p>Hvis du har glemt at tage Ivabradine Zentiva 
Hvis du glemmer at tage en dosis Ivabradine Zentiva, skal du tage den næste dosis til normal tid. Du 
må ikke tage en dobbeltdosis som erstatning for den glemte dosis.  </p>
<p>Hvis du holder op med at tage Ivabradine Zentiva 
Behandlingen for angina pectoris og kronisk hjertesvigt er sædvanligvis livslang. Tal med din læge, 
før du holder op med at tage denne medicin.<br />
Tal med din læge eller apotekspersonalet, hvis du mener, at virkningen af Ivabradine Zentiva er for 
kraftig eller for svag. </p>
<p>Spørg lægen eller apotekspersonalet, hvis der er noget, du er i tvivl om.  </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. 
De almindeligste bivirkninger med dette lægemiddel er dosisafhængige og relaterede til dets 
virkningsmåde: </p>
<p>Meget almindelig (kan forekomme hos flere end 1 ud af 10 personer) 
- Lysfænomener (kortvarige lysglimt, der ofte skyldes pludselige forandringer i lysets intensitet). 
De kan også beskrives som en ring, farvede lysglimt, billedopløsning eller mangfoldige billeder. 
De forekommer almindeligvis inden for de første to måneder af behandlingen, hvorefter de kan 
forekomme gentagne gange og forsvinde under eller efter behandlingen.  </p>
<p>Almindelig (kan forekomme hos op til 1 ud af 10 personer)<br />
- Ændret hjertefunktion (viser sig ved, at pulsen bliver langsommere). Det forekommer især inden 
for de første 2 til 3 måneder efter indledning af behandlingen.  </p>
<p>Andre bivirkninger er også blevet rapporteret:  </p>
<p>Almindelig (kan forekomme hos op til 1 ud af 10 personer) 
- Uregelmæssig hurtig sammentrækning af hjertet (atrieflimren), unormal fornemmelse af 
hjerteslag (bradykardi, ventrikulære ekstrasystoler, AV-blok af 1. grad (forlænget PQ-interval i 
ekg)), ukontrolleret blodtryk, hovedpine, svimmelhed og uskarpt syn (uklart syn). </p>
<p>Ikke almindelig (kan forekomme hos op til 1 ud af 100 personer) 
- Hjertebanken og ekstra hjerteslag, kvalme, forstoppelse, diarré, mavesmerter, fornemmelse af at 
verden drejer rundt (vertigo), åndedrætsbesvær (åndenød), muskelspasmer, forhøjet urinsyre i 
blodet, for mange hvide blodlegemer (af typen eosinofile granulocytter) og forhøjede 
blodværdier for kreatinin (et nedbrydningsprodukt, som dannes i musklerne), hududslæt, 
angioødem (viser sig som hævelser i ansigt, tunge eller hals eller besvær med at trække vejret 
eller synke), lavt blodtryk, besvimelse, træthed, svaghed, abnorm ekg-diagram, dobbeltsyn, 
nedsat syn.  </p>
<p>Sjælden (kan forekomme hos op til 1 ud af 1.000 personer) 
- Nældefeber, kløe, rødme af huden, utilpashed.  </p>
<p>Meget sjælden (kan forekomme hos op til 1 ud af 10.000 personer)<br />
- Uregelmæssig puls (AV-blok af 2. grad og 3. grad, syg sinus-syndrom). </p>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge eller apotekspersonalet. Dette gælder også 
mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også 
indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i 
Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information 
om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store ivabradine"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store ivabradine"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på kartonen og blisteren efter "EXP". 
Udløbsdatoen er den sidste dag i den nævnte måned. </p>
<p>Opbevar lægemidlet ved temperaturer under 25 °C. Opbevares i den originale pakning for at beskytte 
mod fugt. </p>
<p>Spørg apotekspersonalet, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke 
smide medicinrester i afløbet, toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Ivabradine Zentiva indeholder:</p>
<ul>
<li>Aktivt stof: ivabradin (som hydrochlorid). Hver filmovertrukket tablet indeholder 5 mg 
ivabradin (som hydrochlorid) eller 7,5 mg ivabradin (som hydrochlorid).  </li>
<li>Øvrige indholdsstoffer:<br />
Tabletkerne: Mannitol, crospovidon (type A), magnesiumstearat 
Filmovertræk: Hypromellose (6 mPa·s, type 2910), titandioxid (E172), macrogol 400, glycerol 
(E422).  </li>
</ul>
<p>Udseende og pakningsstørrelser 
Ivabradine Zentiva 5 mg filmovertrukne tabletter er runde, bikonvekse hvide tabletter med dyb 
delelinje på den ene side og præget '5' på den anden side med diameter 6,5 mm. Tabletten kan deles i 
to lige store doser. 
Ivabradine Zentiva 7,5 mg filmovertrukne tabletter er hvide til råhvide, runde tabletter med en 
diameter på 7,1 mm.<br />
Ivabradine Zentiva er pakket i Opa/Alu/PVC-Alu blister og i karton. </p>
<p>Tabletterne fås i pakninger med 14, 28, 56, 84, 98, 100, 112 filmovertrukne tabletter. </p>
<p>Ikke alle pakningsstørrelser er nødvendigvis markedsført. </p>
<p>Indehaver af markedsføringstilladelsen<br />
Zentiva, k.s. 
U Kabelovny 102 37 Prag Tjekkiet </p>
<p>Fremstiller 
Zentiva, k.s. 
U Kabelovny 102 37 Prag Tjekkiet </p>
<p>eller </p>
<p>S.C. Zentiva S.A 
50 Theodor Pallady Blvd, 
District 3, 
032266 Bukarest 
Rumænien </p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen: </p>
<p>België/Belgique/Belgien 
Zentiva, k.s. 
Tél/Tel: +32 280 86 PV-Belgium@zentiva.com </p>
<p>Lietuva 
Zentiva, k.s. 
Tel: +370 52152PV-Lithuania@zentiva.com 
България 
Zentiva, k.s. 
Тел: + 35924417PV-Bulgaria@zentiva.com </p>
<p>Luxembourg/Luxemburg 
Zentiva, k.s. 
Tél/Tel: +352 208 82PV-Luxembourg@zentiva.com 
Česká republika 
Zentiva, k.s. 
Tel: +420 267 241 PV-Czech-Republic@zentiva.com 
Magyarország 
Zentiva Pharma Kft. 
Tel.: +36 1 299 1PV-Hungary@zentiva.com 
Danmark 
Zentiva Denmark ApS 
Tlf: +45 787 68 PV-Denmark@zentiva.com </p>
<p>Malta 
Zentiva, k.s. 
Tel: +356 2778 0PV-Malta@zentiva.com 
Deutschland 
Zentiva Pharma GmbH<br />
Tel: +49 (0) 800 53 53 PV-Germany@zentiva.com </p>
<p>Nederland 
Zentiva, k.s. 
Tel: +31 202 253 PV-Netherlands@zentiva.com 
Eesti 
Zentiva, k.s. 
Tel: +372 52 70PV-Estonia@zentiva.com </p>
<p>Norge 
Zentiva Denmark ApS 
Tlf: +47 219 66 PV-Norway@zentiva.com 
Ελλάδα 
Zentiva, k.s. 
Τηλ: +30 211 198 7PV-Greece@zentiva.com </p>
<p>Österreich 
Zentiva, k.s. 
Tel: +43 720 778 PV-Austria@zentiva.com 
España 
Zentiva, k.s. 
Tel: +34 931 815 PV-Spain@zentiva.com </p>
<p>Polska 
Zentiva Polska Sp. z o.o. 
Tel: + 48 22 375 92 PV-Poland@zentiva.com 
France 
Zentiva France 
Tél: +33 (0) 800 089 219<br />
PV-France@zentiva.com </p>
<p>Portugal 
Zentiva Portugal, Lda 
Tel: +351210601PV-Portugal@zentiva.com 
Hrvatska 
Zentiva d.o.o. 
Tel: +385 1 6641 PV-Croatia@zentiva.com </p>
<p>România 
ZENTIVA S.A. 
Tel: +4 021.304.7PV-Romania@zentiva.com </p>
<p>Ireland 
Zentiva, k.s. 
Tel: +353 818 882 PV-Ireland@zentiva.com </p>
<p>Slovenija 
Zentiva, k.s. 
Tel: +386 360 00 PV-Slovenia@zentiva.com 
Ísland 
Zentiva Denmark ApS 
Sími: +354 539 0PV-Iceland@zentiva.com </p>
<p>Slovenská republika 
Zentiva, a.s. 
Tel: +421 2 3918 3PV-Slovakia@zentiva.com 
Italia 
Zentiva Italia S.r.l. 
Tel: +39-02-38598PV-Italy@zentiva.com 
Suomi/Finland 
Zentiva Denmark ApS 
Puh/Tel: +358 942 598 PV-Finland@zentiva.com </p>
<p>Κύπρος 
Zentiva, k.s. 
Τηλ: +357 240 30 PV-Cyprus@zentiva.com </p>
<p>Sverige 
Zentiva Denmark ApS 
Tel: +46 840 838 PV-Sweden@zentiva.com 
Latvija 
Zentiva, k.s. 
Tel: +371 67893PV-Latvia@zentiva.com 
United Kingdom (Northern Ireland) 
Zentiva, k.s. 
Tel: +44 (0) 800 090 2PV-United-Kingdom@zentiva.com </p>
<p>Denne indlægsseddel blev senest ændret  </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu.  </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-bbb651a1913e568b3035dea752ef36ea
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for ivabradine Package Leaflet for language en"
Description: "ePI document Bundle for ivabradine Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-bbb651a1913e568b3035dea752ef36ea"
* entry[0].resource = composition-en-bbb651a1913e568b3035dea752ef36ea

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpbbb651a1913e568b3035dea752ef36ea"
* entry[=].resource = mpbbb651a1913e568b3035dea752ef36ea
                            
                    
Instance: bundlepackageleaflet-da-bbb651a1913e568b3035dea752ef36ea
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for ivabradine Package Leaflet for language da"
Description: "ePI document Bundle for ivabradine Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-bbb651a1913e568b3035dea752ef36ea"
* entry[0].resource = composition-da-bbb651a1913e568b3035dea752ef36ea

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpbbb651a1913e568b3035dea752ef36ea"
* entry[=].resource = mpbbb651a1913e568b3035dea752ef36ea
                            
                    



Instance: mpbbb651a1913e568b3035dea752ef36ea
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Ivabradine Zentiva 5 mg film-coated tablets"
Description: "Ivabradine Zentiva 5 mg film-coated tablets"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "Ivabradine Zentiva 5 mg film-coated tablets"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Ivabradine Zentiva 5 mg film-coated tablets"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: bbb651a1913e568b3035dea752ef36eaListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "ivabradine"

* status = #current
* mode = #working

* title = "List of all ePIs associated with ivabradine"

* subject = Reference(mp9f905123b19c0e055435474ad8fd13e5)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#ivabradine "ivabradine"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-bbb651a1913e568b3035dea752ef36ea) // ivabradine en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-bbb651a1913e568b3035dea752ef36ea) // ivabradine da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-bbb651a1913e568b3035dea752ef36ea
InstanceOf: List

* insert bbb651a1913e568b3035dea752ef36eaListRuleset
    